Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

By Magnus Ingelman-Sundberg. TIPS - Trends in Pharmacological Sciences, 2004

671 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/a623116376ee884e4158f271bf4ecedb0c04197a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pharmacology

Citations in the corpus

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, background): “Recently, some reviews have covered the topic regarding the use of pharmacogenetics in drug treatment (Ingelman-Sundberg, 2004; Eichelbaum et al., 2006; Gardiner & Begg, 2006).”
The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis (2006, background): “Variant alleles can sometimes cause an intermediate-metabolism or a poor-metabolism phenotype, the latter of which results in low (or no) enzyme activit”
Molecular Systems Biology Peer Review Process File Indi: a Computational Framework for Inferring Drug Interactions and Their Associated Recommendations Transaction Report (neutral): “The latter may enable physi cians to seek alternative medications involving different drug-CYP interactions, as well as considering patient-specific genetic polymorphisms related to certain CYP enzymes (Bertilsson, 1995; Goshman et al, 1999) (e.g., patients who are CYP2D6-deficient (Ingelman-Sundbe”
Cytochrome P450 Enzymes and Drug Metabolism in Humans (2021, background): “In addition to gene polymorphisms, epigenetic mechanisms, such as DNA methylation, which can regulate expression of CYP genes by targeting either the promoter region or upstream transcriptional factors, can also affect the variability of CYPs [49,57].”
Pharmacogenomics and individualized drug therapy. (2006, background): “Approximately 20%–25% of all drugs in clinical use are metabolized at least partly by CYP2D6 (46).”